Virology Core

$106,547U19FY2018AINIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39289557 Paper 39121848 Paper 39121847 Paper 38900877 Paper 38311121 Paper 38263597 Paper 38260304 Paper 38231127 Paper 38213787 Paper 38091951 Paper 37948331 Paper 37735591 Paper 37439558 Paper 37291427 Paper 37256718 Paper 37236193 Paper 37169862 Paper 37131713 Paper 37095348 Paper 37027481 Paper 36972796 Paper 36824931 Paper 36816340 Paper 36798171 Paper 36747786 Paper 36594081 Paper 36479446 Paper 36461941 Paper 36415470 Paper 36271148 Paper 36261003 Paper 36244343 Paper 36223726 Paper 36208629 Paper 35914921 Paper 35902637 Paper 35759301 Paper 35736236 Paper 35716846 Paper 35618829 Paper 35523182 Paper 35508657 Paper 35507919 Paper 35348420 Paper 35263570 Paper 35090584 Paper 35022275 Paper 34893640 Paper 34882194 Paper 34878969 Paper 34874183 Paper 34765984 Paper 34648302 Paper 34622480 Paper 34535642 Paper 34522051 Paper 34521836 Paper 34496014 Paper 34467988 Paper 34462751 Paper 34453880 Paper 34448809 Paper 34424310 Paper 34399607 Paper 34334359 Paper 34312547 Paper 34312545 Paper 34312544 Paper 34282425 Paper 34237028 Paper 34196300 Paper 34193339 Paper 34171305 Paper 34147519 Paper 34103408 Paper 34051040 Paper 34017137 Paper 34006921 Paper 33979613 Paper 33969320 Paper 33907765 Paper 33858945 Paper 33851179 Paper 33688691 Paper 33653907 Paper 33636129 Paper 33631096 Paper 33594383 Paper 33574619 Paper 33564756 Paper 33542081 Paper 33452106 Paper 33444817 Paper 33277626 Paper 33125080 Paper 33119750 Paper 33116245 Paper 33083029 Paper 32728222 Paper 32727884

Abstract

The Virology Core will be responsible for the generating full-length viral genome sequences from the majority of study subjects in this U19 through a highly organized, and high-throughput 454 sequencing approach. As these data can be generated rapidly, these data will also serve to identify subjects and epitopes for downstream analysis for the proposed specific studies on outlined in Projects 1-4. To rule out any confounding effects on our study design of possible virus-specific interferon resistance associated with prior interferon therapy failure, the Virology Core will also determine whether there is any evidence of genotypic resistance to interferon in subjects previously having failed interferon therapy. Specifically, the Virology Core will: Aim 1: Characterize full genome viral sequences from all HCV+ study subjects to identify epitope-specific sequence data for downstream phenotype and functional assays. Aim 2: Determine whether subjects who failed to achieve prior sustained virologic response (SVR) under interferon and ribavirin therapy exhibit any IFN genotypic resistance markers

View original record on NIH RePORTER →